Making Evidence-based Decisions Using Alzheimer Therapy (MEDUSA Therapy)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55568578

Enrollment

Registered

2004-09-30

Start date

2003-09-30

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease Nervous System Diseases Alzheimer's disease

Interventions

Randomised controlled trial (RCT): 1. Cholinesterase inhibitor (ChEi) as usual 2. Increased dose of ChEi 3. Rivastigmine 4. Memantine 5. ChEi as usual, plus memantine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 75 participants (i.e. 15 in each arm of the trial) with diagnosis of Alzheimer's disease (AD) and aged between 55 and 95

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Clinical Global Impression of Change (CGI/C) 2. Mini-Mental State Examination (MMSE) 3. BAYER-Activities of Daily Living (ADL) 4. Neuropsychiatric inventory questionnaire (NPI-Q) 5. Global Assessment Scale (GAS)	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026